Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.

Author(s)
Tanaka, Motoko; Yoshida, Kazuki; Fukuma, Shingo; Ito, Kazuko; Matsushita, Kazutaka; Fukagawa, Masafumi; Fukuhara, Shunichi; Akizawa, Tadao

Citation
PLOS ONE (2016), 11(10)

Issue Date
2016-10-20

URL
http://hdl.handle.net/2433/217099

Right
© 2016 Tanaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Type
Journal Article
RESEARCH ARTICLE

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study

Motoko Tanaka1†, Kazuki Yoshida2,3, Shingo Fukuma3,4, Kazuko Ito1, Kazutaka Matsushita1, Masafumi Fukagawa5, Shunichi Fukuhara4,6, Tadao Akizawa7

1 Department of Nephrology, Akebono Clinic, Kumamoto, Japan, 2 Departments of Epidemiology & Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, 3 Institute for Health Outcomes and Process Evaluation Research (IHope International), Kyoto, Japan, 4 Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan, 5 Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan, 6 Department of Innovative Research and Education for Clinicians and Trainees (DIRECT), Fukushima Medical University Hospital, Fukushima, Japan, 7 Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

* tanaka@matusita-kai.or.jp

Abstract

Objectives

Anemia is an important prognostic factor in hemodialysis patients. It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement of postoperative erythropoiesis-stimulating agents. The objective of this study was to assess the effect of cinacalcet, which is considered as a pharmacological parathyroidectomy, on anemia in hemodialysis patients.

Methods

We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism; the criteria were: intact parathyroid hormone concentrations ≥ 180 pg/mL or use of an intravenous or oral vitamin D receptor activator. All patients were cinacalcet-naïve at study enrollment. The main outcome measure was achievement of the target hemoglobin level (≥10.0 g/dL), which was measured repeatedly every 6 months. Cinacalcet exposure was defined as cumulative time since initiation. Both conventional longitudinal models and marginal structural models were adjusted for confounding factors.

Results

Among 3,201 cinacalcet-naïve individuals at baseline, cinacalcet was initiated in 1,337 individuals during the follow up. Cinacalcet users were slightly younger; included more patients with chronic glomerulonephritis and fewer with diabetes; were more likely to have a history of parathyroidectomy; and were more often on activated vitamin D agents, phosphate binders, and iron supplements. After adjusting for both time-invariant and time-changing potential factors...
confounders, including demographics, comorbidities, comediations, and laboratory values, each additional 6-month duration on cinacalcet was associated with a 1.1-fold increase in the odds of achieving the target hemoglobin level.

Conclusions
Cinacalcet may improve anemia in chronic hemodialysis patients with secondary hyperparathyroidism, possibly through pathways both within and outside the parathyroid hormone pathways. Further investigations are warranted to delineate the roles of cinacalcet not only in the management of chronic kidney disease–mineral and bone disorder but also in anemia control.

Introduction
Anemia is an important complication of chronic maintenance hemodialysis and is known to be an important predictor of poor prognosis[1,2]. Many factors contribute to anemia in dialysis patients, such as decreased production of erythropoietin, resistance to erythropoietin, shortened survival of red blood cells (RBC), and diminished erythropoiesis[3–5]. Additionally, secondary hyperparathyroidism (SHPT), a major component of chronic kidney disease–mineral and bone disorder (CKD–MBD), is known to result in resistance to erythropoietin; shortened survival of RBC via the accumulation of high levels of parathyroid hormone (PTH), a uremic substance; and decreased hematopoiesis due to myelofibrosis, which partially explains the pathways linking CKD and anemia[5,6].

It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement for postoperative erythropoiesis-stimulating agents. In recent years, vitamin D receptor activators (VDRA) have been shown to improve anemia in chronic hemodialysis patients through pleiotropic effects on the immune system, inflammation, and nutritional status, in addition to the SHPT-related pathways[7–9]. Similar studies have been conducted for the newly marketed cinacalcet, a calcimimetic drug used to treat SHPT, which is considered to be a form of pharmacological parathyroidectomy[10,11].

However, the relationship between cinacalcet use and improvement in anemia has not been clarified in a larger scale longitudinal study. We hypothesized that cinacalcet initiators (patients who initiate cinacalcet) would experience better anemia control (hemoglobin ≥ 10.0 g/dL) compared with that experienced by cinacalcet non-initiators (those who do not initiate cinacalcet), after adjusting for both baseline and time-varying confounders. Thus, we conducted a longitudinal analysis of a large cohort of hemodialysis patients with SHPT in daily clinical practice to investigate the effect of cinacalcet on improvement of anemia.

Materials and Methods
Data Source
The Mineral and Bone Disorder Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D) was a 3-year, multicenter, prospective case-cohort, and cohort study of hemodialysis patients with SHPT. The eligibility criteria were as follows: (i) under hemodialysis at a participating facility as of January 1, 2008 and (ii) intact PTH (iPTH) concentrations ≥ 180 pg/mL or receipt of intravenous VDRA (calcitriol or maxacalcitol) or oral active VDRA treatment (falecalcitriol, the only oral VDRA approved in Japan for SHPT treatment at the time of
Details of the study design have been described previously[12]. Most data were collected at 3- or 6-month intervals. As hemoglobin was measured every 6 months, we utilized the 6-month interval data in this analysis. This study was approved by the Central Ethics Committee at the Kobe University School of Medicine. The study was conducted in accordance with the principles of the Declaration of Helsinki, and the MBD-5D study was registered at ClinicalTrials.gov (NCT00995163).

Study Population

Only the patients in the predefined subcohort were included in this study. Patients with cancer or cancer-related comorbidity at the time of enrollment were excluded from the analysis; and if a patient was diagnosed with cancer during the observation period, data obtained post-diagnosis were not included in the analysis.

Outcomes

The primary outcome of interest was achievement of the target hemoglobin level ($\geq 10.0$ g/dL). Hemoglobin levels were assessed as the secondary outcome. Both outcomes were repeatedly measured in each individual every 6 months, up to a maximum of six measurements.

Exposure

Cinacalcet use was the exposure of interest. To emulate the intention-to-treat effect[13] in the randomized controlled trials, we defined a time-varying “ever exposed” status variable. That is, patients contributed “unexposed” observations until they initiated cinacalcet; and, once initiated, these patients always contributed “exposed” observations regardless of their current cinacalcet use status. This time-varying “ever exposed” status was then converted to a “time since initiation” variable to account for the dose response over time. As the study enrollment period was prior to the market approval of cinacalcet in Japan, all patients were cinacalcet-naïve at baseline, allowing for a clear definition of cinacalcet initiation (new user design).

Covariates

Clinically relevant variables that could influence subsequent cinacalcet use and hemoglobin levels were considered to be confounders that required adjustment. These included demographics such as age and gender, baseline comorbidities such as the cause of CKD, smoking status, diabetes mellitus, heart disease, cerebrovascular disease, and duration of maintenance hemodialysis history. Any history of hyperparathyroidism treatment (parathyroidectomy, and ethanol or vitamin D injection therapy) was also assessed at baseline. Baseline-only laboratory tests included creatinine and total protein. Information on these variables was provided by each patient’s treating physician.

Comedications and laboratory test values were time-varying. Medications included intravenous or oral activated vitamin D, phosphate binders (either calcium-containing or otherwise), erythropoiesis-stimulating agents, and iron supplements. Time-varying laboratory test values included Kt/V, intact PTH (calculated from the whole PTH level using the equation $iPTH = \text{whole PTH} \times 1.7$ as direct assays differed between study sites)[14,15], albumin-adjusted serum calcium (calcium–albumin–4.0)[16], serum phosphate, alkaline phosphatase, albumin, ferritin, iron, and hemoglobin.

To ensure the time-varying covariates, exposure, and outcome were correctly ordered, and also to avoid reverse causality (where the outcome precedes the covariates), the covariate values were obtained 6 months prior to the exposure, which in turn was ascertained 6 months prior to...
In the sensitivity analysis, the lagged exposure status 12 months prior to the outcome was used to examine the potentially delayed effect of cinacalcet on hemoglobin.

**Statistical analysis**

Continuous variables were expressed as means and standard deviations or as medians with 25th and 75th percentiles, as appropriate. Categorical variables were summarized as count and proportion. As the exposure varied over time, we present the baseline characteristics at the time of study enrollment separately for patients who initiated cinacalcet at some point during the follow-up and for those who did not start at any time during the follow-up. Group imbalance was examined with the standardized mean difference[17]; in general, a standardized mean difference greater than 0.1 was considered as indicating group imbalance. For clinically relevant variables required for the adjusted regression models, missing values were imputed with multiple imputation using the mice package in R[18]. Cinacalcet initiation over time was described using Kaplan–Meier estimation techniques. An unadjusted description of mean hemoglobin level was calculated at each time point for patients who started cinacalcet (“calcinet users,” in the intention-to-treat sense) and those who remained off cinacalcet (“non-users”).

In the regression analysis, the generalized estimating equation (GEE) model was used to account for the within-patient correlation of longitudinal, repeatedly measured outcomes. For the primary outcome of achievement of the target hemoglobin level (≥10 g/dL), the GEE longitudinal logistic model was used. For the secondary outcome of continuous hemoglobin level, the GEE longitudinal linear model was used.

Assessment of the effect of time-varying exposure was complicated by the presence of time-varying confounders, clinical characteristics influenced by previous treatment that affect the subsequent treatment choices and outcomes of interest[19]. These time-varying characteristics may therefore be potential confounders and mediators at the same time. To account for these variables, we employed two strategies: use of the conventional GEE model incorporating time-varying covariates, and use of a marginal structural model[19]. Marginal structural models with the inverse probability of treatment weighting (IPTW) estimator[19] are increasingly used to disentangle complex time-varying confounding because they can provide better confounding control in such a situation. Due to the longitudinal nature of the outcome data, we constructed a marginal structural model for the repeatedly measured outcomes[20].

An exploratory analysis among the cinacalcet users assessed changes in iPTH, calcium, and phosphate and hemoglobin over time. Also an ad hoc subgroup analysis based on the median iPTH value (265.20 pg/ml) was conducted to examine the influence of the baseline iPTH value at the study enrollment. All analyses were conducted with R version 3.3 (www.r-project.org) and its additional packages `tableone`, `mice`, `geepack`, and `survey`. Hypothesis tests were considered statistically significant when p < 0.05.

**Results**

At the baseline, the registry included 3,201 chronic hemodialysis patients with secondary hyperparathyroidism. Among these, 1,337 patients initiated cinacalcet at some point during the follow-up (44.6% by the end of follow-up; Fig 1, left panel), constituting the initiators. The baseline characteristics of the future initiators (none of whom were on cinacalcet at enrollment) and the cinacalcet non-users are presented in Table 1. Compared with the non-users, the prospective calcinet users showed the following characteristics at their visit 6 months prior to cinacalcet initiation: younger age (mean 58.9 years vs 63.9 years), a greater likelihood of chronic glomerulonephritis being the reason for hemodialysis (53.3% chronic glomerulonephritis and...
15.7% diabetic nephropathy vs 39.1% chronic glomerulonephritis and 30.1% diabetic nephropathy), longer duration of hemodialysis (median 10.9 years vs 5.8 years), more frequent surgical therapy for secondary hyperparathyroidism (10.8% vs 4.9%), more frequent vitamin D agent use (86.9% vs 73.8%), more frequent phosphate binder use (91.8% vs 81.6%), slightly more frequent erythropoietic agent use (71.4% vs 69.3%), slightly more frequent iron supplement use (19.7% vs 14.1%), higher adjusted calcium (mean 10.2 mg/dL vs 9.4 mg/dL), higher inorganic phosphate (mean 5.8 mg/dL vs 5.4 mg/dL), and slightly higher hemoglobin (10.65 g/dL vs 10.44 g/dL).

The mean hemoglobin levels at each time point for those who had started cinacalcet by that time and for those who had not are plotted in Fig 1 (right panel). The hemoglobin levels were slightly higher at each time point for those patients who had started cinacalcet (Users) than for those who had remained off cinacalcet (Non-users), with the difference varying from 0.1 to 0.2 g/dL. As noted earlier, there were no cinacalcet users at the time of study enrollment. Changes in several variables before and after cinacalcet initiation are shown in Fig 2. As expected, iPTH increased steeply before cinacalcet initiation and decreased dramatically afterwards. Serum calcium and phosphate showed a modest decline after initiation. Activated vitamin D doses varied greatly between individuals; the mean value decreased after cinacalcet initiation. Erythropoiesis-stimulating agent use and iron supplement use were stable after initiation of cinacalcet (around 70% for erythropoiesis-stimulating agent and around 20% for iron supplement).

In the unadjusted GEE model (Table 2), the use of cinacalcet for 6 months was associated with a 1.1-fold increase in the odds of achieving the target hemoglobin level of ≥10 g/dL (odds ratio 1.13, 95% confidence interval [1.09, 1.17], p < 0.001). The mean change in hemoglobin level for each additional 6-month use of cinacalcet was +0.064 g/dL [0.047, 0.081], p < 0.001 (Table 3).

The adjusted models were controlled for age, sex, time since enrollment, primary cause of chronic kidney disease, smoking status, diabetes, ischemic heart disease, congestive heart
Table 1. Characteristics of the cinacalcet non-users at registry enrollment and of the cinacalcet initiators at the visit immediately prior to cinacalcet initiation.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Non-users (enrollment)</th>
<th>Users (pre-initiation)</th>
<th>SMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>1864</td>
<td>1337</td>
<td></td>
</tr>
<tr>
<td>Age, years (mean (SD))</td>
<td>63.86 (12.81)</td>
<td>58.88 (11.78)</td>
<td>0.405</td>
</tr>
<tr>
<td>Male (%)</td>
<td>1168 (62.7)</td>
<td>800 (59.8)</td>
<td>0.058</td>
</tr>
<tr>
<td>Primary disease (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic glomerulonephritis</td>
<td>728 (39.1)</td>
<td>712 (53.3)</td>
<td>0.400</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>561 (30.1)</td>
<td>210 (15.7)</td>
<td></td>
</tr>
<tr>
<td>Chronic pyelonephritis</td>
<td>31 (1.7)</td>
<td>25 (1.9)</td>
<td></td>
</tr>
<tr>
<td>Polycystic kidney</td>
<td>67 (3.6)</td>
<td>72 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Hypertensive nephrosclerosis</td>
<td>130 (7.0)</td>
<td>58 (4.3)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>347 (18.6)</td>
<td>260 (19.4)</td>
<td></td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>202 (10.8)</td>
<td>149 (11.1)</td>
<td>0.010</td>
</tr>
<tr>
<td>Diabetes</td>
<td>715 (38.4)</td>
<td>282 (21.1)</td>
<td>0.385</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>499 (26.8)</td>
<td>298 (22.3)</td>
<td>0.104</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>158 (8.5)</td>
<td>80 (6.0)</td>
<td>0.096</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>113 (6.3)</td>
<td>58 (4.4)</td>
<td>0.082</td>
</tr>
<tr>
<td>Chronic hemodialysis duration, years [median (IQR)]</td>
<td>5.82 [2.53, 11.44]</td>
<td>10.94 [6.81, 16.84]</td>
<td>0.532</td>
</tr>
<tr>
<td>History of surgical therapy (%)</td>
<td>92 (4.9)</td>
<td>145 (10.8)</td>
<td>0.221</td>
</tr>
<tr>
<td>Parathyroidectomy</td>
<td>84 (4.5)</td>
<td>107 (8.0)</td>
<td>0.145</td>
</tr>
<tr>
<td>Ethanol injection</td>
<td>7 (0.4)</td>
<td>32 (2.5)</td>
<td>0.177</td>
</tr>
<tr>
<td>Vitamin D injection</td>
<td>10 (0.6)</td>
<td>21 (1.7)</td>
<td>0.102</td>
</tr>
<tr>
<td>Baseline creatinine, mg/dL [mean (SD)]</td>
<td>10.74 (2.84)</td>
<td>11.97 (2.73)</td>
<td>0.442</td>
</tr>
<tr>
<td>Baseline total protein, g/dL [mean (SD)]</td>
<td>6.57 (0.55)</td>
<td>6.54 (0.53)</td>
<td>0.059</td>
</tr>
<tr>
<td>IV or oral activated vitamin D use (%)</td>
<td>1376 (73.8)</td>
<td>1162 (86.9)</td>
<td>0.334</td>
</tr>
<tr>
<td>Total activated vitamin D dose Âµg/4 weeks</td>
<td>4.00 [0.00, 7.00]</td>
<td>6.45 [3.50, 9.00]</td>
<td>0.412</td>
</tr>
<tr>
<td>Phosphate binder use (%)</td>
<td>1521 (81.6)</td>
<td>1227 (91.8)</td>
<td>0.303</td>
</tr>
<tr>
<td>Erythropoietin use (%)</td>
<td>1292 (69.3)</td>
<td>955 (71.4)</td>
<td>0.046</td>
</tr>
<tr>
<td>Iron supplement use (%)</td>
<td>263 (14.1)</td>
<td>263 (19.7)</td>
<td>0.149</td>
</tr>
<tr>
<td>Body mass index [mean (SD)]</td>
<td>21.35 (3.63)</td>
<td>21.35 (3.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Kt/V [median (IQR)]</td>
<td>1.38 [1.20, 1.56]</td>
<td>1.46 [1.30, 1.62]</td>
<td>0.286</td>
</tr>
<tr>
<td>Intact parathyroid hormone, pg/mL [median (IQR)]</td>
<td>237.85 [185.50, 328.02]</td>
<td>340.00 [223.00, 506.60]</td>
<td>0.517</td>
</tr>
<tr>
<td>Serum calcium, mg/dL [mean (SD)]</td>
<td>9.13 (0.83)</td>
<td>9.98 (0.73)</td>
<td>1.094</td>
</tr>
<tr>
<td>Adjusted serum calcium, mg/dL [mean (SD)]</td>
<td>9.40 (0.95)</td>
<td>10.22 (0.5)</td>
<td>0.908</td>
</tr>
<tr>
<td>Serum phosphate, mg/dL [mean (SD)]</td>
<td>5.37 (1.35)</td>
<td>5.80 (1.32)</td>
<td>0.321</td>
</tr>
<tr>
<td>Alkaline phosphatase, IU/L [median (IQR)]</td>
<td>248.00 [190.00, 336.50]</td>
<td>256.00 [198.00, 346.00]</td>
<td>0.074</td>
</tr>
<tr>
<td>Albumin, g/dL [mean (SD)]</td>
<td>3.73 (0.37)</td>
<td>3.76 (0.35)</td>
<td>0.088</td>
</tr>
<tr>
<td>Serum ferritin, ng/mL [mean (SD)]</td>
<td>198.63 (365.08)</td>
<td>148.81 (209.23)</td>
<td>0.167</td>
</tr>
<tr>
<td>Serum iron, Âµg/dL [median (IQR)]</td>
<td>58.00 [44.00, 75.00]</td>
<td>59.00 [45.00, 76.00]</td>
<td>0.002</td>
</tr>
<tr>
<td>Hemoglobin, g/dL [mean (SD)]</td>
<td>10.44 (1.19)</td>
<td>10.65 (1.09)</td>
<td>0.182</td>
</tr>
<tr>
<td>Hemoglobin &lt; 10 g/dL (%)</td>
<td>600 (32.2)</td>
<td>329 (24.6)</td>
<td>0.169</td>
</tr>
</tbody>
</table>

Abbreviations: SD: standard deviation; IQR: interquartile range; SMD: standardized mean difference

doi:10.1371/journal.pone.0164865.t001

failure, chronic hemodialysis duration, history of surgical therapy for hyperparathyroidism, baseline creatinine, baseline total protein, comediations (activated vitamin D, phosphate binders, erythropoietin-stimulating agents, iron supplements), and laboratory measures (Kt/V, intact parathyroid hormone, albumin-adjusted serum calcium, phosphate, alkaline phosphatase, albumin, ferritin, serum iron, and hemoglobin level at the previous visit). The adjusted
Fig 2. Trajectories of laboratory findings and medication use for the cinacalcet users before and after cinacalcet initiation.

doi:10.1371/journal.pone.0164865.g002

| Table 2. Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on the odds of achieving the treatment target (intention-to-treat effect). |
|------------------|------------------|------------------|
| Hemoglobin ≥ 10 g/dl as a binary outcome | OR [95% CI] | p |
| Generalized estimating equation | | |
| Unadjusted | 1.13 [1.09, 1.17] | <0.001 |
| Fully adjusted | 1.08 [1.04, 1.13] | <0.001 |
| Inverse probability of treatment weight | | |
| Fully adjusted | 1.11 [1.04, 1.20] | 0.013 |

Abbreviations: OR: odds ratio; CI: confidence interval.

doi:10.1371/journal.pone.0164865.t002
regression results for the binary outcome of achievement of target hemoglobin level are presented in Table 2. The conventional adjusted GEE model showed an adjusted odds ratio for each additional 6-month use of cinacalcet of 1.08 (1.04, 1.13), \( p < 0.001 \). The IPTW-based marginal structural model (Table 2) adjusting for the same set of variables gave a similar result for the odds of achieving the target hemoglobin level [adjusted odds ratio 1.11 (1.04, 1.20), \( p = 0.013 \)].

The adjusted regression results for the outcome of continuous mean hemoglobin levels are presented in Table 3. The conventional adjusted GEE model showed an adjusted effect per each additional 6 months of cinacalcet use of +0.042 g/dL (0.019, 0.066), \( p = 0.001 \). The IPTW-based marginal structural model gave a slightly higher result [adjusted mean difference +0.067 g/dL (0.020, 0.114), \( p = 0.020 \)].

In the exploratory analysis among the cinacalcet users, the hemoglobin trajectories were most clearly differentiated throughout the study period between those whose phosphate level had increased and those whose level had declined. The trajectories were not as clearly separated by similar differences in iPTH or calcium levels (S1 Fig). In the subgroup analysis, those who had higher-than-median baseline iPTH had numerically higher improvement in anemia than those who had lower-than-median baseline iPTH (adjusted odds ratio 1.09 (1.04, 1.14) vs 1.07 (1.00, 1.15) in GEE; adjusted odds ratio 1.14 (1.05, 1.25) vs 1.07 (0.99, 1.17) in IPTW), however, the group difference did not reach statistical significance (\( p = 0.657 \) for GEE; \( p = 0.304 \) for IPTW).

**Discussion**

In order to clarify the effect of cinacalcet use on the anemia control status, we conducted an analysis of the MBD-5D prospective cohort of chronic hemodialysis patients. We found that each additional 6 months on cinacalcet was associated with an approximately 1.1-fold increase in the odds of maintaining the anemia control target of hemoglobin \( \geq 10 \) g/dL. When measured on the continuous mean hemoglobin-level scale, we also found that each additional 6 months on cinacalcet was associated with a hemoglobin increment of 0.042–0.067 g/dL. These findings suggest the potential benefit of cinacalcet use for the control of anemia in chronic hemodialysis patients with SHPT.

SHPT is known to be one of the pathological conditions that cause anemia[21,22], and SHPT and anemia coexist in most hemodialysis patients. Indeed, as many as 70% of the present study subjects had anemia and were receiving an erythropoietin-simulating agent. However, in routine clinical settings SHPT and anemia are often managed separately and from different viewpoints. When physicians manage anemia only by controlling the hemoglobin level with erythropoietin-simulating agents, few would notice whether the use of cinacalcet improved the
anemia. The association between cinacalcet use and improvement of anemia in the present study suggests that it could be possible to manage SHPT and anemia simultaneously in an integrated manner.

Our findings are consistent with the hypothesis, based on the findings of basic science papers\[5,23\], that blockage of high parathyroid hormone levels may improve anemia in patients with secondary hyperparathyroidism. Although non-significant due to reduced sample sizes, the exploratory subgroup analysis by the baseline iPTH demonstrated numerically higher effects in those who had higher-than-median baseline iPTH levels. SHPT is known to cause anemia via several possible pathways. Erythrocyte lifespans decrease in response to high PTH levels\[24\]; and high PTH levels inhibit hematopoietic stem cell activity, particularly that of erythroid burst-forming units, as well as inducing myelofibrosis and contributing to erythropoietin resistance\[24,25\].

Curative parathyroidectomy has been reported to improve myelofibrosis in patients with primary hyperparathyroidism, thereby improving anemia\[26,27\]. Another retrospective report has described the potential benefits of parathyroidectomy in secondary hyperparathyroidism \[28\]. The authors reported that, after parathyroidectomy, the use of erythropoietin-stimulating agents was rendered unnecessary. These findings suggest that parathyroidectomy induces a reduction in PTH levels and an improved resistance to vitamin D, thereby inducing improvements in anemia and erythropoietin resistance. This deduction is in accordance with the findings of the present study regarding improvement of anemia with cinacalcet, which is considered to be a form of “medical parathyroidectomy.”

Cinacalcet is also likely to participate in improving anemia via pathways not driven by PTH levels. Calcium-sensing receptors play a role in the homing of hematopoietic stem cells to bone marrow niches as well as in engraftment promotion\[29\]. The allosteric action of cinacalcet is likely to act against the calcium-sensing receptors on hematopoietic stem cells, thus contributing to anemia improvement. Recently, Koizumi et al.\[30\] reported that administration of cinacalcet reduced the serum level of fibroblast growth factor 23 in patients with SHPT. Similar data were also obtained from the EVOLVE study\[31\]. Also, Coe et al.\[31\] found that loss of fibroblast growth factor 23 increased erythrocyte production in mice. Therefore, in addition to reducing PTH, reduction of fibroblast growth factor 23 may be one pathway through which cinacalcet improves anemia.

Our study is not without limitations. As we utilized a cohort of SHPT patients (from the MBD-5D study), the generalizability of our findings beyond this type of patient (i.e., chronic hemodialysis patients in general) is unknown. As with any observational studies, problems with unmeasured (or unmeasurable) confounders cannot be ruled out. The present study did not record the dosage of comediations that could influence hemoglobin levels (erythropoiesis-stimulating agents and iron supplements), the patients’ activities of daily living, their nutritional intake status, or inflammatory markers. However, these factors are less likely to affect the decision to initiate cinacalcet (the exposure). Outcome predictors that are not strongly associated with determining exposure have only limited potential to be confounders\[32\]. Usage of erythropoiesis-stimulating agents and iron supplements did not change after cinacalcet initiation. Thus, we could speculate that their dosage probably did not change dramatically. The mean ferritin level decreased after cinacalcet initiation, thus, adjustment in anemia treatment may have benefited these patients further.

Our study had several important strengths. The MBD-5D cohort is a large-scale prospective cohort of chronic hemodialysis patients, which has collected a rich set of data at regular intervals, allowing assessment of time-varying exposure and the control of time-dependent confounding. The cohort’s focus on SHPT patients can be considered as its strength. It allowed us to analyze a cohort of patients with relatively similar backgrounds. The enrollment period of
the cohort was prior to the market approval of cinacalcet in Japan; thus, no patients were on cinacalcet at baseline. The new user design is generally recommended in medication studies [33], as it allows clearer distinction of what prompted medication use, and what resulted from this. We employed two types of statistical analysis to adjust for time-dependent confounding, namely the conventional longitudinal GEE model and the IPTW-based marginal structural model. In this instance, we found relatively similar results from both analyses. The subtle differences are likely to be due to the handling of covariates after cinacalcet initiation.

In conclusion, we found that each additional 6 months on cinacalcet was associated with a 1.1-fold increase in the odds of achieving the hemoglobin control target of $\geq 10$ g/dL in chronic hemodialysis patients with secondary hyperparathyroidism. However, the increment of the increase in hemoglobin was relatively small, and further investigations are warranted to define the roles of cinacalcet not only in CKD-MBD management but also in anemia control.

### Supporting Information

**S1 Fig. Hemoglobin trajectories among cinacalcet initiators.** The users are grouped according to whether there was a decline or increase in the laboratory findings. (TIFF)

**S1 Table. Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on the odds of achieving the treatment target (12-month lagged outcome).** (DOCX)

**S2 Table. Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on hemoglobin levels (12-month lagged outcome).** (DOCX)

### Acknowledgments

We would like to thank the MBD-5D study advisory investigators, Masashi Suzuki (Shinrakuen Hospital), Yoshindo Kawaguchi (Shiomidai Hospital), Akira Saito (Shonan Tobu Sougo Hospital), Yoshiki Nishizawa (Osaka City University Graduate School of Medicine), Yusuke Tsukamoto (Itabashi Chuo Medical Center), Satoshi Kurihara (Tsukinomori Clinic), Takashi Akiba (Tokyo Women’s Medical University), Eriko Kinugasa (Showa University Northern Yokohama Hospital), Yuzo Watanabe (Kasugai Municipal Hospital), Yoshihiro Tominaga (Nagoya Daini Red Cross Hospital), Takashi Shigematsu (Wakayama Medical University), Masaaki Inaba (Osaka City University Graduate School of Medicine), Jun Minakuchi (Kawashima Hospital), Hideki Hirakata (Fukuoka Red Cross Hospital), Keitaro Yokoyama (Jikei University School of Medicine), Naoki Kimata (Tokyo Women’s Medical University), Fumihiko Koiwa (Showa University Fujigaoka Hospital), Ryoichi Ando (Musashino Red Cross Hospital), Junichiro J. Kazama (Niigata University), Takatoshi Kakuta (Tokai University School of Medicine), Hirotaka Komaba (Tokai University School of Medicine), Daijo Inaguma (Nagoya Daini Red Cross Hospital), Eiji Ishimura (Osaka City University Graduate School of Medicine), Hideki Tahara (Osaka University Graduate School of Medicine), Kazuhiro Tsuruya (Kyu-shu University), Akira Fujimori (Konan Hospital), and Ryo Kido (Inagi Municipal Hospital).

The following investigators also participated in this study: Nobuo Hashimoto (H•N•MEDIc), Mari Ishida (Kitasaito Hospital), Toshiyuki Date (Date Clinic), Kiyotaka Yabuki (Yabuki Hospital), Hideki Tanida (Tendo Onsen Yabuki Clinic), Fumitoshi Yamauchi (San-ai Hospital), Mikihiko Fujishima (Yahaba Clinic), Tomohito Matsunaga (Eijinkai Hospital), Jun Urase (Ishinomaki Clinic), Hiroshi Kawaguchi (Iwaki Urological Hospital), Ikuko Takahashi (Kisen Hospital), Yoshiko Tanaka (Shinjuku Ishikawa Clinic), Hideo Kobayashi (Suda Clinic), Maki
Takahashi (Suda Naika Clinic), Tatsuya Nonaka (Seishokai Memorial Hospital), Hideto Emoto (Tokai Hospital), Kyosuke Nishio (Shinko-kaClinical), Atsushi Hayama (Moriyama Rehabilitation Hospital), Toshiho Shinoda (Kawakita General Hospital Dialysis Center), Takashi Kono (Mihama Narita Clinic), Takahiro Mochizuki (Kameda Medical Center), Yasuo Kimura (Shin-kashiwa Clinic), Noriyoshi Murotani (Chiba Social Insurance Hospital), Satoshi Yamaguchi (Asahi Hospital), Taichi Nakanishi (Kurihama Clinic), Kiyoshi Ozawa (Yokosuka Clinic), Takashi Nagaoka (Sagamihara Clinic), Takao Suga (Bousei Hiratsuka Clinic), Masakazu Suda (Suda Medical Clinic), Yoshikazu Goto (Saiyu Soka Hospital), Michio Kuwahara (Shuwa General Hospital Hemodialysis Clinic), Hiromi Komiyama (Yuuai Clinic), Kimihiko Matsuyama (Mizato Kenwa Clinic), Kazue Ueki (Toho Hospital), Kyoko It (Heisei Hidaka Clinic), Katsuhiko Miyamoto (Mikuni Center), Takashi Ishizu (Tukuba Central Hospital), Shuichi Kikuchi (Obara Renal Clinic), Masaki Kobayashi (Tokyo Medical University Ibaraki Medical Center), Mitsuyoshi Furuhashi (Maruyama Hospital), Masanori Wakabayashi (Bousei Daiichi Clinic), Kazuyoshi Nakamura (Fujidaiichi Clinic), Hirotake Kasuga (Kaikoukai Central Clinic), Itsuo Yokoyama (Nagoya Memorial Foundation Narumi Clinic), Chikao Yamazaki (Matsukino Clinic SUBARU), Kiju Nagata (Sawada Hospital), Yusumasa Kawate (Suzuka Kidney Clinic), Toshiaki Kawanaka (Ichikiriseiki Hospital), Yoshihiro Tsumimoto (Inoue Hospital), Mikio Okamura (Ohno Memorial Hospital), Shigeki Okada (Okada Clinic), Senji Okuno (Kidney Center Shirasagi Clinic), Harumi Nagayama (Nagayama Hemodialysis Clinic), Shuji Okazaki (Nagayama Hospital), Yoshinori Tone (Fujii Clinic), Ikuki Yaji (Ibuki Clinic), Kouji Shibuya (Sumiyoshigawa Hospital), Kunihiko Yoshiya (Hara Genitourinary Hospital), Morhiro Kondou (Otowa Kinen Hospital), Satoru Yamazaki (Tojinkai Hospital), Ryoichi Miyazaki (Fujita Memorial Hospital), Katsuhiko Arimoto (Shigei Medical Research Hospital), Misaki Morishii (Nakaigawa Tsutaya Clinic), Takahito Nasu (Tokuyama Central Hospital), Seiichi Obayashi (Kinashi Obayashi Hospital), Yuzuru Sato (Sato Junkanka Naikai), Takao Tanaka (Ohji Hospital), Hidetoshi Nakamura (Kokura Daichi Hospital), Nobuhiko Koga (Shin-Koga Clinic), Harumichi Higaishi (St. Mary's Hospital), Kougi Yum (Takahashi Naika Clinic), Asako Kitamura (Chikuhi Social Insurance Hospital), Tomoji Matsumae (Murakami Memorial Hospital), Katsuhige Abe (Jinikai Hospital), Masahiro Kawatomi (Kawatomi Internal Medicine Clinic), Chisa Nogami (Kumamoto Urological Hospital), Itsuo Yoshidome (Ikeda Hospital), Shinya Miyagi (Okayama Daichi Hospital), Satoshi Nakazato (Chibana Clinic), Yoshiki Shiohira (Tomishiro Central Hospital), and Kiyoyuki Tokuyama (Tokuyama Clinic).

Author Contributions

Conceptualization: MT.

Formal analysis: KY S.Fukuma.

Investigation: MT MF S.Fukuhara TA.

Supervision: KI KM MF S.Fukuhara TA.

Writing – original draft: MT KY.

Writing – review & editing: S.Fukuma KI KM MF S.Fukuhara TA.

References


